Meeting
2012 ASCO Annual Meeting
ARCHER: Dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC)—A randomized double-blind phase III study.
Authors
Michael J. Boyer
Sydney Cancer Centre, Camperdown, Australia
Michael J. Boyer , Pasi A. Janne , Tony Mok , Kenneth John O'Byrne , Luis G. Paz-Ares , Suresh S. Ramalingam , Jane Q Liang , Ian Taylor , Alicyn Campbell , Joseph P. O'Connell , Stephen P. Letrent , Vladan Antic
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01360554
Citation
J Clin Oncol 30, 2012 (suppl; abstr TPS7615)
DOI
10.1200/jco.2012.30.15_suppl.tps7615
Abstract #
TPS7615
Poster Bd #
54A
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Randomized, double-blinded study of dacomitinib, an irreversible pan-human epidermal growth factor receptor (HER) inhibitor, versus erlotinib for second-line/third-line therapy of locally advanced/metastatic non-small cell lung cancer (ARCHER 1009).
First Author: Suresh S. Ramalingam
Poster
2018 ASCO Annual Meeting
A multicenter, randomized, double-blind, placebo-controlled phase III study of apatinib or placebo plus gefitinib as first-line treatment in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC).
First Author: Hongyun Zhao
Poster
2017 Gastrointestinal Cancers Symposium
Phase II trial of capecitabine +/- erlotinib in advanced colorectal cancer, with retrospective KRAS and primary tumor site analysis.
First Author: Daniel Adam Breadner
Poster
2015 ASCO Annual Meeting
Final follow-up (f/u) results from RADIANT: A randomized double blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection in patients (pts) with stage IB–IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC).
First Author: Mary E.R. O'Brien